Amvis : Q2Q2 FAQ （730KB）

First Half Ended March 31, 2023

FAQ

Amvis Holdings, Inc.

May 15, 2023

©Amvis Holdings, Inc.

Summary

1. Number of Facilities / Bed Capacity

1. Utilization Rates
   Q Net Sales
   Q Operating Profit / EBITDA
   Q Cash Flow
   Q Facility Opening Strategy

1. Recruiting

1. Promoting Occupancy

1. Headquarters-FocusedSystem

1. Wage Increase

1. Competition

1. Macro Environment

1. COVID-19

1. Changing Market Listing / Secondary Offering

1. Shareholder Return

1. Sustainability

1. Regional Healthcare Revitalization Project

1. IR Activities

©Amvis Holdings, Inc.	2

Key Financial Indicators:

Number of Facilities / Bed Capacity

Q

A

How do you plan to expand the number of facilities / bed capacity?

We continue to accelerate the openings of Ishinkan to reach the Amvis 2025 target of 127 facilities (6,328 beds).

We have already announced plans to open 19 new facilities and expand 1 facility (1,021 beds) for FY23, and we plan to further accelerate facility openings toward the end of FY25.

The basic capacity per facility is about 50 beds. We also aim to open about 1-2 large facilities with 70 beds per year.

©Amvis Holdings, Inc.	3

Key Financial Indicators: Utilization Rates

Q

A

What are your current utilization rates and forecast for FY23?

In FY23 1H, we maintained stable operation at existing facilities, and the start of 8 new facilities was also favorable as we expected. Utilization rates as a whole surpassed our target for stable operations.

As forecast for FY23 2H and later, we continue to expect the utilization rate to be 82-85%, which is our target for stable operations.

Since Ishinkan mainly accepts patients in the terminal stages of cancer, about 10 patients per month are leaving or passing away at each facility, which makes it difficult to maintain the utilization rates in the 90% range.

©Amvis Holdings, Inc.	4

Key Financial Indicators: Net Sales

Q

A

What is your analysis of net sales for FY23 1H?

As mentioned on the previous page, utilization rates were favorable. As a result, net sales were also in line with our expectations. In FY23 1H, we reached

48.0% of our full-year forecast. In FY23, we expect net sales to be immaterially different from our initial forecast.

To reflect energy price hikes, we raised patient payments by about 3,000 yen per month in October 2022 and by about 4,000 yen per month in March 2023.

We will keep working to increase net sales by increasing the number of facilities (bed capacity) and maintaining utilization rates.

©Amvis Holdings, Inc.	5